Effect of OPRM1 Polymorphism on Morphin and Oxycodone Drug Dosage
Objective:To clarify whether different genotypes have impacts on equivalent doses of mor-phine,and determine whether there is a difference between the doses of morphine and hydrocodone under the same genotype.Methods:OPRM1 gene testing was performed on cancer pain patients admitted to our oncology department from July 2020 to December 2021,with an NRS score of≥4 and opioid intolerance.The patients were divided into 6 groups based on the test results,and the daily required doses of mor-phine or oxycodone were recorded.The doses of oxycodone used were converted into equivalent morphine doses,and the differences in equivalent morphine doses were compared.Results:The equivalent morphine doses required for AG or GG subtypes were significantly higher than those for AA subtypes.Under AG or GG subtypes,the doses required for the use of oxycodone were significantly lower than those of morphine.Conclusion:The use of opioid drugs in cancer pain patients with morphine intolerance is influenced by the OPRM1 genotype polymorphism.Patients carrying the G allele require larger amount of opioid drugs,and choosing oxycodone can achieve better results than morphine.
万方数据
维普
